Egis in the World
Egis’ products reach more than 100 countries around the world.
Egis’ products reach more than 100 countries. Our main focus lies on treating diseases of the cardiovascular and central nervous systems.
Learn moreOur activities incorporate all areas in the pharmaceutical value chain
Click here to learn moreOne of the fundamental pillars of our strategy is innovation.
Click here to learn moreTwo of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.
Csaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.
If you suspect an adverse reaction related to the use of EGIS, or a suspected quality problem or counterfeit, please contact: